Regeneron Pharmaceuticals (REGN) Shares Outstanding (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Shares Outstanding (Entity) of $102.8 million for Q2 2026, down 2.19% year-over-year from $105.1 million in Q2 2025, and down 1.15% quarter-over-quarter from $104.0 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Shares Outstanding (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Shares Outstanding (Entity) history runs 18 years deep, the most recent figure standing at $102.8 million for Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) fell 2.19% year-over-year to $102.8 million; the TTM figure through Jun 2026 stood at $102.8 million (down 2.19% YoY), while the FY2025 annual figure was $104.6 million, down 3.06% from the prior year.
- Shares Outstanding (Entity) for Q2 2026 stood at $102.8 million, down from $104.0 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $128.3 million in Q2 2022, with the low at $102.8 million in Q2 2026.
- The 5-year median for Shares Outstanding (Entity) is $107.0 million (2022), against an average of $108.6 million.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) rose 4.73% in 2022, then declined 16.6% in 2023.
- Regeneron Pharmaceuticals' Shares Outstanding (Entity) stood at $107.1 million in 2022, then slipped by 0.37% to $106.7 million in 2023, then increased by 1.12% to $107.9 million in 2024, then dropped by 3.06% to $104.6 million in 2025, then slipped by 1.72% to $102.8 million in 2026.
- Business Quant data shows REGN's Shares Outstanding (Entity) at $102.8 million in Q2 2026, $104.0 million in Q1 2026, and $104.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 720.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.80 Mn |
| Mar 31, 2026 | 104.00 Mn |
| Dec 31, 2025 | 104.60 Mn |
| Sep 30, 2025 | 103.60 Mn |
| Jun 30, 2025 | 105.10 Mn |
| Mar 31, 2025 | 106.70 Mn |
| Dec 31, 2024 | 107.90 Mn |
| Sep 30, 2024 | 108.10 Mn |
| Jun 30, 2024 | 108.10 Mn |
| Mar 31, 2024 | 107.80 Mn |
| Dec 31, 2023 | 106.70 Mn |
| Sep 30, 2023 | 106.30 Mn |
| Jun 30, 2023 | 107.00 Mn |
| Mar 31, 2023 | 107.10 Mn |
| Dec 31, 2022 | 107.10 Mn |
| Sep 30, 2022 | 106.90 Mn |
| Jun 30, 2022 | 107.90 Mn |
| Mar 31, 2022 | 106.80 Mn |
| Dec 31, 2021 | 105.70 Mn |
| Sep 30, 2021 | 106.20 Mn |